Bionano Genomics (BNGO) investor relations material

Company overview and business model

• Provides genome analysis solutions, including optical genome mapping (OGM), nucleic acid extraction, diagnostic services, and software for research and clinical applications.

• Offers OGM systems (Saphyr, Stratys), Ionic Purification system, and VIA software for cytogenomics and molecular pathology labs.

• Expanded through acquisitions of Lineagen, BioDiscovery, and Purigen, transitioning from an instrument company to a full-suite genomic solutions provider.

• Focuses on maximizing utilization of installed OGM systems and cost-saving initiatives, with less emphasis on new placements.

Financial performance and metrics

• Has incurred recurring net losses and expects to continue incurring losses; substantial doubt exists regarding ability to continue as a going concern.

• Recurring losses, negative cash flows, and significant accumulated deficit require additional capital in the near term.

Use of proceeds and capital allocation

• Net proceeds intended for general corporate purposes, including working capital, R&D, repayment or redemption of existing indebtedness, and capital expenditures.

• May use a portion for acquisitions or investments in complementary businesses, products, or technologies, though no current commitments exist.

• Pending use, proceeds will be invested in money market funds, U.S. government obligations, commercial paper, certificates of deposit, and corporate bonds.